Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for Neurocrine Biosciences (NBIX) over the last 9 years, with Q1 2018 value amounting to $731000.0.

  • Neurocrine Biosciences' Current Deferred Revenue fell 7942.0% to $731000.0 in Q1 2018 from the same period last year, while for Mar 2018 it was $731000.0, marking a year-over-year decrease of 7942.0%. This contributed to the annual value of $731000.0 for FY2017, which is 7926.83% down from last year.
  • Neurocrine Biosciences' Current Deferred Revenue amounted to $731000.0 in Q1 2018, which was down 7942.0% from $731000.0 recorded in Q4 2017.
  • Over the past 5 years, Neurocrine Biosciences' Current Deferred Revenue peaked at $10.2 million during Q4 2015, and registered a low of $731000.0 during Q2 2017.
  • Moreover, its 5-year median value for Current Deferred Revenue was $3.3 million (2015), whereas its average is $3.2 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Current Deferred Revenue skyrocketed by 20685.92% in 2015 and then tumbled by 7942.0% in 2018.
  • Neurocrine Biosciences' Current Deferred Revenue (Quarter) stood at $3.3 million in 2014, then skyrocketed by 206.86% to $10.2 million in 2015, then plummeted by 65.43% to $3.5 million in 2016, then tumbled by 79.27% to $731000.0 in 2017, then changed by 0.0% to $731000.0 in 2018.
  • Its last three reported values are $731000.0 in Q1 2018, $731000.0 for Q4 2017, and $731000.0 during Q3 2017.